StocksMedium•6 November 2026•
1 min read
Alector Reports $124.6 Million Q3 Net Income Following GSK Deal Termination
Key Facts
1Alector reported a net income of $124.6 million for the third quarter of 2026.
2The profit was primarily driven by the recognition of deferred revenue following the termination of its agreement with GSK.
Alector reported a net income of $124.6 million for the third quarter of 2026, Benzinga reported. The profit was primarily driven by the recognition of deferred revenue following the termination of its collaboration agreement with GSK, marking a significant shift in the company's quarterly performance.
ALEC closed at $2.09 on November 5, 2026, while GSK closed at $50.41 on the same date. According to company filings, collaboration revenue reached $162.9 million for the quarter ended September 30, 2026, up from $3.3 million in the prior year, while research and development expenses stood at $30.0 million.